Pharmaceuticals

Global Blood Based Biomarkers Market Size Projected to Reach $40.66 Billion During the Forecast Period

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Blood Based Biomarkers Market Expected To Expand Between 2025 And 2029?

The blood based biomarkers market has witnessed substantial expansion in recent years. This market is set to increase from $23.13 billion in 2024 to $25.83 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.6%. The historical growth of this market can be ascribed to several factors, including the escalating global incidence of cancer, the expanding adoption of personalized medicine, augmented funding for biomarker research, the proliferation of clinical trials incorporating biomarkers, and an uptick in approvals for companion diagnostics.

The blood based biomarkers market is projected for significant expansion, reaching “$40.66 billion by 2029, with a compound annual growth rate (CAGR) of 12.0%. This anticipated growth is driven by factors such as the broader application of AI and machine learning in analyzing biomarkers, a heightened need for detecting diseases at an early stage, the advancement of telemedicine and remote diagnostic tools, the increasing incidence of chronic illnesses, and a greater public understanding of health issues. Key developments expected during this period involve AI-powered biomarker discovery, progress in liquid biopsy techniques, the incorporation of multi-omics data, the development of point-of-care (POC) testing devices, and breakthroughs in next-generation sequencing (NGS).

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

Which Drivers Are Impacting The Blood Based Biomarkers Market?

The increasing incidence of cardiovascular diseases is anticipated to drive the expansion of the blood-based biomarkers market. These diseases are a category of disorders impacting the heart and blood vessels, encompassing conditions like coronary artery disease, heart failure, and stroke. The escalation in cardiovascular diseases is largely attributable to mounting risk factors such as poor dietary habits and rising obesity rates. Blood-based biomarkers are instrumental in the diagnosis and monitoring of cardiovascular diseases, offering understanding into disease progression, risk assessment, and treatment response through measurable substances found in the blood. For instance, in September 2024, the National Center for Biotechnology Information, a US-based government agency, shared insights from a global health research initiative. This report projected a 90% surge in cardiovascular disease prevalence between 2025 and 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. Therefore, the rising number of cardiovascular disease cases is fueling the growth of blood-based biomarkers.

What Are The Major Segments Identified In The Blood Based Biomarkers Market?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

What Are The Latest Industry Trends Transforming The Blood Based Biomarkers Market?

Leading companies within the blood-based biomarkers market are concentrating on technological breakthroughs, such as highly accurate blood biomarker tests, to assist physicians in diagnosing Alzheimer’s disease. A high-accuracy blood biomarker test functions as a diagnostic instrument that identifies diseases or monitors health conditions with significant precision and reliability by utilizing specific blood biomarkers. For example, in October 2023, Quanterix, a US-based life sciences company, introduced LucentAD p-Tau 217, a high-accuracy blood biomarker test aimed at supporting physicians in the diagnosis of Alzheimer’s disease (AD) in adults who have cognitive impairment. This test quantifies phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker strongly linked to AD pathology, especially the buildup of amyloid in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, meeting strict diagnostic criteria, and is designed for use in combination with other diagnostic tools, not as a solitary test.

Which Key Players Are Driving Competition In The Blood Based Biomarkers Market?

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Region Currently Holds The Largest Share Of The Blood Based Biomarkers Market?

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Blood Based Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

Browse Through More Reports Similar to the Global Blood Based Biomarkers Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795